SHELBY LIM: Open Payments
NPI 1316602568 · FULLERTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,140 in 64 payments from 26 companies in 2025. Trend: 2023 $1,047 · 2024 $2,355 · 2025 $3,140
Food & beverage: $3,140
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 8 | $548 |
| AstraZeneca Pharmaceuticals LP | 4 | $272 |
| Gilead Sciences, Inc. | 2 | $214 |
| Boston Scientific Corporation | 4 | $192 |
| Edwards Lifesciences Corporation | 1 | $169 |
| Novartis Pharmaceuticals Corporation | 7 | $155 |
| Alnylam Pharmaceuticals Inc. | 7 | $143 |
| Lilly USA, LLC | 2 | $142 |
| Phathom Pharmaceuticals, Inc. | 1 | $127 |
| Exact Sciences Corporation | 1 | $125 |
Products named: Repatha, LOKELMA, Otezla, WATCHMAN FLX, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), LEQVIO, AMVUTTRA, MOUNJARO.
Industry payments across CA — which companies pay providers there.
